title: Antitumor immunity by a dendritic cell vaccine encoding secondary lymphoid chemokine and tumor lysate on murine prostate cancer.
abstract: OBJECTIVE
  To investigate the antitumor immunity by a dendritic cell (DC) vaccine encoding secondary lymphoid chemokine gene and tumor lysate on murine prostate cancer.
  
  
  METHODS
  DC from bone marrow of C57BL/6 were transfected with a plasmid vector expressing secondary lymphoid chemokine (SLC) cDNA by Lipofectamine 2,000 liposome and tumor lysate. Total RNA extracted from SLC+lysate-DC was used to verify the expression of SLC by reverse transcriptase-polymerase chain reaction (RT-PCR). The immunotherapeutic effect of DC vaccine on murine prostate cancer was assessed.
  
  
  RESULTS
  We found that in the prostate tumor model of C57BL/6 mice, the administration of SLC+lysate-DC inhibited tumor growth most significantly when compared with SLC-DC, lysate-DC, DC or phosphate buffer solution (PBS) counterparts (P < 0.01). Immunohistochemical fluorescent staining analysis showed the infiltration of more CD4(+), CD8(+) T cell and CD11c(+) DC within established tumor treated by SLC+lysate-DC vaccine than other DC vaccines (P < 0.01).
  
  
  CONCLUSIONS
  DC vaccine encoding secondary lymphoid chemokine and tumor lysate can elicit significant antitumor immunity by infiltration of CD4(+), CD8(+) T cell and DC, which might provide a potential immunotherapy method for prostate cancer.
authors.affiliation: Department of Urology, Shanghai Jiao Tong University, Affiliated First People's Hospital, Shanghai 200080, China. lj0063@msn.com
authors.forename: Jun
authors.initials: J
authors.lastname: Lu
authors.forename: Qi
authors.initials: Q
authors.lastname: Zhang
authors.forename: Chun-Min
authors.initials: CM
authors.lastname: Liang
authors.forename: Shu-Jie
authors.initials: SJ
authors.lastname: Xia
authors.forename: Cui-Ping
authors.initials: CP
authors.lastname: Zhong
authors.forename: Da-Wei
authors.initials: DW
authors.lastname: Wang
mesh_terms: D000818:Animals; D000912:Antibodies, Neoplasm / Q000096:biosynthesis; D000951:Antigens, Neoplasm / Q000276:immunology; D018845:CD11 Antigens / Q000276:immunology; D019496:Cancer Vaccines / Q000276:immunology* / Q000627:therapeutic use*; D002460:Cell Line; D018925:Chemokines / Q000096:biosynthesis*; D003713:Dendritic Cells / Q000276:immunology* / Q000378:metabolism*; D000939:Epitopes / Q000276:immunology; D005455:Fluorescent Antibody Technique; D007694:Killer Cells, Natural / Q000276:immunology; D008214:Lymphocytes / Q000378:metabolism*; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D009368:Neoplasm Transplantation; D010957:Plasmids / Q000235:genetics; D011471:Prostatic Neoplasms / Q000276:immunology / Q000473:pathology / Q000517:prevention & control*; D020133:Reverse Transcriptase Polymerase Chain Reaction; D013601:T-Lymphocytes / Q000276:immunology
chemical_list: D000912:Antibodies, Neoplasm; D000951:Antigens, Neoplasm; D018845:CD11 Antigens; D019496:Cancer Vaccines; D018925:Chemokines; D000939:Epitopes